AmpC Beta-lactamase, Bacteremia
Conditions
Keywords
AmpC beta-lactamase, Bacteremia, Piperacillin, Tazobactam
Brief summary
Nosocomial bloodstream infections are important causes of morbidity and mortality caused by AmpC beta-lactamase-producing Enterobacteriaceae. The information collected will optimize the management of patients with nosocomial bloodstream infections.
Detailed description
The following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, and past medical history. We will collect information retrospectively.
Interventions
None listed
Sponsors
Japan Health Sciences Foundation
University of Pittsburgh
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinical information is collected by chart review of case and control patients. A case patient is defined as follows: * One or more blood cultures are positive for E. cloacae, E. aerogenes, C. freundii, S. marcescens or M. morganii. * The patient received piperacillin/tazobactam as the initial empiric therapy. * The organism was susceptible to piperacillin/tazobactam. * A control patient is defined as follows: * One or more blood cultures are positive for E. cloacae, E. aerogenes, C. freundii, S. marcescens or M. morganii. * The patient received a carbapenem or fluoroquinolone antimicrobial as the initial empiric therapy. * The organism was susceptible to the empiric regimen.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| dead or alive | end of study | health status |
Countries
United States
Outcome results
None listed